tranylcypromine has been researched along with regorafenib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, NM; Wu, LW; Zhang, C; Zhang, JK; Zhang, ZY; Zhou, DM; Zhu, HJ | 1 |
1 other study(ies) available for tranylcypromine and regorafenib
| Article | Year |
|---|---|
Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Demethylases; Humans; Hydrazines; Kaplan-Meier Estimate; Liver Neoplasms; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Serine; Sulfonamides; Tranylcypromine | 2019 |